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Background: It is not known whether antibiotic therapy for lung disease in cystic ﬁbrosis (CF) has an inﬂuence on circulating polymorphonuclear
neutrophil (PMN) function and apoptosis.
Patients and methods: Blood PMNs were obtained from 14 CF patients before and after antibiotic treatment for an acute exacerbation, and from 10
healthy controls. PMNs were evaluated for production of reactive oxygen species (ROS) by spectrophotometry, of cytokines in the conditioned
medium by ELISA, and apoptotic response by cytoﬂuorimetry.
Results: ROS and interleukin (IL)-8 were produced at higher levels by CF PMNs pre-therapy than control PMNs under basal conditions. IL-8
levels further increased after therapy. Early apoptotic response was higher in CF PMNs pre-therapy than in control PMNs, and this pattern did not
change after antibiotic treatment.
Conclusions: Circulating PMNs are primed in CF acute patients. Further studies are needed to consider PMN-produced IL-8 as a biomarker to
evaluate response to antibiotic therapy in CF patients.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Antibiotics; Apoptosis; Cytokines; Blood neutrophils; Reactive oxygen species1. Introduction
Cystic fibrosis (CF) is the most common lethal inherited disease
in the Western world, and affects many organs and tissue.
Nevertheless, respiratory failure accounts for more than 80% of
deaths from the disease, usually in the third or fourth decade of life.
Clinical symptoms in CF are the consequence of mutations in the
CF transmembrane conductance regulator (CFTR) gene on⁎ Corresponding author. Tel.: +39 0881 588019; fax: +39 0881 588037.
E-mail address: m.conese@unifg.it (M. Conese).
1 Pasqualina Montemurro and Maria A. Mariggiò should be considered as
ﬁrst authors.
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.04.010chromosome 7. Mutations in the CFTR gene cause lack/
dysfunction of the CFTR protein in airway epithelial cells;
however, the mechanism by which the abnormal protein leads to
respiratory disease is not totally understood. One current hypoth-
esis focuses on the airway surface fluid depletion due to abnormal
ion flux ensuing in impaired mucociliary clearance, which in turn
favours respiratory tract infection with opportunistic pathogens,
including Pseudomonas aeruginosa. Thus, the chronic inflamma-
tory response contributes to obstructive lung disease, eventually
leading to respiratory failure [1,2]. High concentrations of
chemokines, such as IL-8, secreted by macrophages and airway
epithelial cells, are responsible for a sustained accumulation of
polymorphonuclear neutrophil (PMNs) in the airways. However,by Elsevier B.V. All rights reserved.
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airways bringing to exaggerated apoptosis of these cells [3–6].
Rather, cytokines promote the activation of PMNs and the release
of substances such as reactive oxygen species (ROS) and
lysosomal and granule protease enzymes which have the
potential to cause tissue damage [7]. Furthermore, PMNs are
killed by P. aeruginosa, releasing proteases that disable any
neighbouring viable PMNs [8] and P. aeruginosa pyocyanin is
known to impair macrophage engulfment of apoptotic cells in
vitro, possibly impacting upon clearance of apoptotic cells from
the bacterial colonized CF lung [9]. Overall, this hypothesis
focuses on the environmental reprogramming of PMNs once they
have been recruited from the circulation and entered into the
pulmonary tissue.
In principle, this altered inflammatory response might derive
also from abnormal function of circulating PMNs [10]. Indeed,
the concept is emerging that CFTR dysfunction may affect
directly PMN function. Reported abnormalities of blood PMN
function in CF indicate they are primed and include increased
degranulation [11,12], IL-8 production [13], lipoxygenase
products release [14], production of reactive oxygen species
(ROS) and respiratory burst activity [15,16], and reduced
opsonin receptor mobilisation [17] and L-selectin shedding
[18]. Furthermore, recent studies have indicated that apoptosis
of blood CF PMNs appears to be delayed in CF as compared
with healthy controls [19–21]. It is not clear, however, whether
these abnormalities are modulated by antibiotic therapy and
therefore might be useful as sensitive and specific biomarkers
of the lung disease.
In this pilot study, we have addressed whether blood PMNs
from acute CF patients display a deranged activation and apoptotic
responses as compared with healthy control subjects. Furthermore,
we have investigated these parameters after antibiotic therapy.
2. Patients and methods
2.1. Patients
The study was approved by, and performed in accordance
with, the ethical standards of our institutional review boards on
human experimentation. Written informed consent was obtained
from each subject. We enrolled 14 CF patients who had been
admitted at the CF Regional Puglia Center of the Hospital of Bari
for antibiotic therapy during acute respiratory exacerbation.
Inclusion criteria were F508del homozygosity and sensitivity to
at least one antibiotic in sputum culture tests. Exclusion criteria
were pulmonary transplanted patients, resistance to all antibio-
tics, corticosteroid therapy, allergic bronchopulmonary aspergil-
losis, and pregnancy. In all patients, the diagnosis of CF was
established on the basis of the results of two sweat chloride
concentration of N60 Meq/L by Gibson and Cooke procedure
and by the identification of two CF-disease causing mutations in
trans. Results of physical examination, chest radiographs,
pulmonary function tests with determination of forced vital
capacity (FVC, % predicted) and forced expiratory volume in 1 s
(FEV1, % predicted), oxygen saturation (SaO2), C Reactive
Protein (CRP, mg/dL), white blood cell (WBC) counts(n/mm3), and blood PMNs (% of WBC) were recorded at the
time of the admittance. Exacerbation was defined as a
deterioration in symptoms perceived by the patient and included
an increase in cough, sputum production, dyspnea, decline in
FEV1 compared with previous best, and weight loss [22]. CF
patients were evaluated for FEV1, FVC, CRP, WBC counts, and
% blood PMNs after 10 days of antibiotic therapy. Two
antibiotics were used in most patients with different mechan-
isms of action, the choice of which was determined by the
sensitivity of the cultured bacteria; all antibiotics were
administered at the doses recommended in CF [23]. Ten
healthy donors with similar sex and age were used as control
group.
2.2. Isolation of blood PMNs
PMNs were isolated according to standard techniques from
heparin anti-coagulated venous blood from CF pre- and post-
therapy and healthy consenting adults. PMNs were isolated using
dextran sedimentation and Hypaque-Ficoll (Amersham Bio-
sciences) density–gradient separation, followed by hypotonic
lysis of erythrocytes as previously described [24]. PMN viability,
as assessed by trypan blue exclusion assay, was ≥90% prior to
experimental use.
2.3. Superoxide anion generation
PMNs were suspended in serum free RPMI 1640 without
phenol red (Life Technology). One aliquot (1×106) of the
isolated cells was stimulated with fMLP (Sigma), and another
with phorbol 12-myristate 13-acetate (PMA) (Sigma) at a final
concentration of 100 nM and 100 ng/ml respectively, and
incubated for different times at 37 °C (up to 20 min). Cells
were washed with PBS and suspended in standard buffer
(4.58 mM KH2PO4, 8.03 mM NaHPO4 0.5 mM MgCl2, 1%
glucose, 0.033% KCl, 0.76% NaCl and endotoxin free albumin;
pH 7.3). Freshly dissolved cytochrome c was used at 0.08 mM
final concentration. Superoxide anion release was monitored as
change in OD at 550 nm by using a Bio-TEK plate reader (Bio-
TEK Instruments). SOD (Superoxide Dismutase) was used at
250 U in parallel controls and the SOD-inhibitable reduction of
cytochrome c was quantified.
2.4. Cytokine production
PMNs (2×106 cells/ml) were incubated without or with TNF-α
(10 ng/ml), in a 5% CO2 incubator for 18 h at 37 °C. At the end of
the culture, the supernatants were harvested, centrifuged
10 min at 300 ×g and 15 °C, and kept at −20 °C before
cytokine measurements. IL-8 levels were measured in the
conditioned media by a commercial ELISA kit (R&D
System, Minneapolis, MN, USA), with assay sensitivity of
3 pg/mL. The levels of IL-1β, IL-6 and IFN-γ in culture
supernatants were determined by ELISA according to the
manufacturer's instructions (Human Inflammatory Cytokine
array, SearchlightTM, Pierce Endogen, Rockford, IL, USA),
with assay sensitivity of 0.1 pg/mL.
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Apoptosis was detected either on PMNs as soon as isolated
(T0), or PMNs after incubation for 24 h at 37 °C, or PMNs after
PMA stimulation. To this purpose three aliquots of 5×105
PMNs from each sample were processed. PMA was used to a
final concentration of 1 μg/ml in HBSS. After an incubation for
15 min at 37 °C, stimulated PMNs were centrifuged at 2700 ×g
for 5 min. Cell pellets were washed twice in PBS, resuspended
in HBSS and incubated for 24 h at 37 °C. PMNs at T0, PMNs
at 37 °C for 24 h and those PMA-stimulated were washed twice
in HBSS and pelleted at 2700 ×g for 5 min. To analyse
apoptotic PMNs Annexin V-FITC/7-AAD kit (Beckman
Coulter) was used. PMN pellets were resuspended in 100 μl
of ice-cold 1× binding buffer, and 10 μl of Annexin V-FITC
solution and 20 μl of 7-ADD Viability Dye were added. After
an incubation for 15 min in the dark on ice, 400 μl of ice-cold
1× binding buffer were added to cell suspensions. Annexin
V-FITC/7-AAD kit, based on the binding properties of annexin
V to phosphatidylserine and on the specificity of 7-amino-
actinomycin D (7-AAD) for DNA, permits to distinguish four
cell populations. Viable cells showed low Annexin V-FITC and
a low 7-AAD; cells in early apoptosis, in which phosphati-
dylserine appeared on the cell surface, showed high Annexin
V-FITC and a low 7-AAD; cells in late apoptosis, whose
membrane integrity is lost, showed low Annexin V-FITC and a
high 7-AAD; dead cells showed high Annexin V-FITC and a
high 7-AAD. Apoptosis was analysed by flow cytometry
(Coulter Epics XL-MCL).Table 1
Respiratory function tests and hematologic parameters before and after
antibiotic therapy.
Pre-therapy Post-therapy p value
WBC (n/mm3) 9.8 (6.9, 10.5) 8.4 (6.6, 11.3) 0.13
Blood PMNs (% of WBC) 60.8 (57.4, 69.3) 58.4 (54.4, 62.7) 0.17
CRP (mg/dL) 3.8 (2.8, 23.5) 2.8 (1.4, 17.6) 0.09
FEV1 (% predicted) 32.3 (19.9, 71.7) 39.6 (20.9, 79.1) 0.13
FVC (% predicted) 52.2 (35.4, 86.9) 62.5 (34.0, 97.4) 0.49
Values are shown as median (25th percentile, 75th percentile). p values were
calculated using the Wilcoxon signed rank test.2.6. Statistical analysis
Since sample numbers in each group were very small and
the variables considered in this study not always showed a
Gaussian distribution according to the Shapiro Wilcox test, non
parametric tests were applied. In particular, to compare ROS
production at different time points (0, 10 and 20 min) and
apoptosis under different incubation conditions (at isolation,
after incubation at 37 °C with and without PMA), the rank
analysis of variance developed by Friedman was used. When
the results of such analysis were statistically significant, to
evaluate which time point or incubation condition was
responsible for the significance, multiple comparisons were
performed according to Wilcoxon and Wilcox test. A p value of
b0.05 was considered statistically significant. The Wilcoxon
signed rank test for paired data was employed to compare pre
and post therapy levels of cytokines, FEV1, FVC, and blood
inflammatory markers. For IL-1β and IL-6, when the measured
concentration was below the detection limit of the assay, a
value equal to the detection limit of the assay was substituted in
the statistical analysis. Comparison between controls and
patients (before and after therapy) was performed by Wilcoxon
rank unpaired test for non-matched data. Correlation between
variables was performed by Spearman non parametric test. The
analysis was performed with the statistical softwares MedCalc
and SAS.3. Results
3.1. Patient characteristics
The mean age of the CF patients recruited in this study was
28.2 years, range 11–43. Males were 11 (79%). Sputum culture
isolated P. aeruginosa (Pa) alone from five patients, Burkholderia
cenocepacia (Bc) from one patient, Staphylococcus aureus (Sa)
from one patient, Bc and Sa, Pa and Sa, Pa and Scedosporium
apiospermum, Pa and Aspergillum fumigatus, Pa and Sa and
Hemophilus influenzae from one patient each. Antibiotic choice
varied between patients, depending on microbiological suscept-
ibility testing and clinical response. Initial antibiotic choices (one,
two to three antibiotics per patient) included tobramycin (n=5),
ciprofloxacin (n=5), azithromycin (n=5), ceftazidim (n=3),
meropenem (n=1), levofloxacin (n=1), minociclin (n=1), sulfa-
metoxazole/trimetoprim (n=1), amikacin (n=1). Patients with
fungal infections were treated also with itroconazole (for
A. fumigatus) and with voriconazole (for S. apiospermum).
3.2. FEV1 and blood inflammatory markers
Respiratory function tests (FEV1 and FVC) and hematologic
parameters were compared at the start and the end of a course of
antibiotics. Following completion of treatment, there were no
significant differences in FEV1 and FVC and in CRP, WBC
counts, and % PMNs as compared with pre-treatment values
(Table 1).
3.3. ROS production
The production of PMN ROS was evaluated in all groups of
subjects at the baseline and following fMLP stimulation.
Preliminary studies on control PMNs were carried out with cells
primed either with fMLP or PMA, and gave similar results. Taken
altogether the data, both control and CF PMNs showed a
spontaneous as well as fMLP-induced time-dependent increase
in ROS (Fig. 1). To detect differences in treatment and various
time points, the Friedman test was applied. Since an overall
significance of pb0.01 was obtained, multiple comparisons were
performed with Wilcoxon–Wilcox test. In controls, unstimulated
and stimulated PMNs showed a significant increase at 20 min vs.
0 min (pb0.01). In CF patients pre-therapy, both unstimulated
and stimulated PMNs produced higher levels of ROS at 20 min
vs. 0 min (pb0.01 and pb0.05, respectively). In CF patients post-
Fig. 1. ROS production by circulating PMNs. PMNs obtained from control
subjects, CF patients before (CF pre) and after therapy (CF post) were incubated
in the absence or presence of fMLP. ROS were detected in the conditioned
media and expressed as nmoles of superoxide anion per 1×106 PMN. Data are
presented by box and whiskers (25th and 75th percentile) and median (solid
line). Data were analysed by Wilcoxon signed rank test for comparison between
pre- and post-therapy and by Wilcoxon rank unpaired test for comparison
between controls and patients (pre- and post-therapy).
Fig. 2. IL-8 production by circulating PMNs. PMNs obtained from control
subjects, CF patients before (CF pre) and after therapy (CF post) were incubated
in the absence or presence of TNF-α. IL-8 was detected in the conditioned
media following an 18-h incubation. Data are presented by box and whiskers
(25th and 75th percentile) and median (solid line). Data were analysed by
Wilcoxon signed rank test for comparison between pre- and post-therapy and by
Wilcoxon rank unpaired test for comparison between controls and patients (pre-
and post-therapy).
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20 min vs. 0 min (pb0.05). PMNs from CF patients produced
spontaneously more ROS than control PMNs, both before and
after therapy (p=0.05), but the production upon fMLP stimulation
did not differ significantly (Fig. 1).
ROS production was then evaluated in the same CF patients
who received an antibiotic treatment for the acute exacerbation.
There were no significant differences in ROS production between
before and after therapy values.
In CF PMNs pre-therapy, there was a weak negative correlation
between unstimulated ROS levels and WBC (rs=−0496) and
circulating PMNs (rs=−0.445), although not statistically signifi-
cant (p=0.10).
These data strongly suggest that CF patients PMNs are more
activated than control PMNs, as judged by the increased
spontaneous release of ROS, and they are likely exhausted.
Furthermore, the antibiotic therapy does not change this pattern.
3.4. Cytokine secretion
IL-8 secretion was studied as basal and stimulated by TNF-α in
PMNs of control subjects and CF patients (Fig. 2). In control
PMNs, TNF-α significantly stimulated IL-8 production
(p=0.0078). Before therapy, CF patients showed a significantly
increased basal secretion as compared with controls (p=0.0046),
that further increased at the end of the treatment (p=0.0002).
TNF-α stimulation resulted in an increase in IL-8 produc-
tion before and after therapy as compared with control PMNs
(p=0.0001 in both PMNs pre-therapy and post-therapy). Unsti-
mulated and stimulated IL-8 levels were significantly higher
after therapy than before therapy (p=0.0001 and p=0.0023,
respectively).
In CF PMNs post-therapy, there was a weak negative
correlation between stimulated IL-8 levels and WBC (rs=
−0.465), although not statistically significant (p=0.10).IFN-γ was undetectable in the conditioned media of PMN
cultures of all samples. Table 2 reports the values of the other
cytokines secreted by PMNs. IL-1β was undetectable in almost
all unstimulated samples. IL-1β levels were significantly
increased by TNF-α stimulation in PMNs from control
subjects (p=0.0313). PMNs from CF patients before therapy
showed a significant increase in IL-1β upon stimulation
(p=0.0078). IL-1β values in stimulated PMNs from CF post-
therapy were lower than in PMNs from CF pre-therapy,
although not significantly (p=0.0537). IL-6 was produced at
low levels and its level non-significantly increased in control
PMNs following stimulation (p=0.9375). PMNs from CF pre-
therapy showed a significant increase in IL-6 secretion upon
TNF-α stimulation (p=0.0002). The secretion of IL-6 from CF
PMNs after resolution of exacerbation was significantly lower
compared to CF PMNs before resolution of exacerbation
(p=0.006).
Altogether these data show that IL-8 had higher levels in CF
PMNs than in control healthy PMNs and that an antibiotic
therapy course further increased these levels, while IL-6 behaved
the opposite and IL-1β presented the same trend as IL-6.3.5. Apoptosis
Since PMN apoptosis was analysed in different subjects
(controls and CF patients) under different incubation conditions,
data were analysed in the first place by the Friedman test for
overall significance, which gave a pb0.01. Thereafter, multiple
comparisons were performed by the Wilcoxon–Wilcox test. In
PMNs obtained from control subjects, early apoptosis (annexin
V+/7-ADD− cells) was significantly reduced by PMA (pb0.01),
whereas there was no difference in cells in late apoptosis
(annexin V−/7-ADD+ cells). In PMNs obtained from CF
patients before treatment, there was a reduction in PMN survival
Table 2
Cytokine levels in cultured PMNs.
Controls Pre-therapy Post-therapy
Unstim. Stim. Unstim. Stim. Unstim. Stim.
IL-1β 0.1 (0.1, 0.1) 0.3 (0.1, 0.6) 0.1 (0.1, 0.2) 0.5 (0.1, 1.2) 0.1 (0.1, 0.1) 0.1 (0.1, 0.3)
IL-6 0.1 (0.1, 2.3) 0.4 (0.3, 0.6) 0.1 (0.1, 0.3) 0.8 (0.2, 1.3) 0.2 (0.1, 0.5) 0.2 (0.1, 0.4)
Cytokines were measured in conditioned media of PMNs either unstimulated or stimulated with TNF-α (10 ng/ml). Undetectable values were substituted by the
detection limit of the assay (0.1 pg/ml). Values are shown as median (25th percentile, 75th percentile). Data were analysed by Wilcoxon signed rank test for
comparison between pre- and post-therapy and by Wilcoxon rank unpaired test for comparison between controls and patients (pre- and post-therapy).
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an increase in early apoptosis (annexin V+/7-ADD- cells;
pb0.05). This behaviour was replicated by PMNs obtained
from patients after antibiotic therapy. When PMNs from control
subjects were compared with those obtained from patients, no
differenceswere observed in PMNs at isolation (Fig. 3A) and after
incubation at 37 °C (Fig. 3B). However, a significant difference
was noted in PMN survival (annexin V−/7-ADD- cells) with
PMA treatment between controls and patients before and after
therapy (Fig. 3C). V(−)ADD(−) cells were significantly less both
before and after therapy in comparison to controls (pb0.01 for
both comparison). Conversely, early apoptotic PMNs (annexin
V+/7-ADD- cells) were significantly increased in CF patients
before and after therapy as compared with controls (pb0.01 for
both comparison). There was also a significant change in death
(V(+)ADD(+) cells) between control PMNs and those obtained
from patients before and after therapy (pb0.05 for both
comparison). No significant differences were found in the patients
before and after therapy.
4. Discussion
In this study, we show that PMNs isolated from blood of CF
patients with exacerbation are in an activated state, demon-
strated by higher baseline levels of ROS and IL-8 as compared
with healthy controls. PMNs showed a spontaneous generation
of ROS upon keeping them in culture for short times as shown
previously [25], likely due to the manipulation during the
isolation procedure [26]. However these levels were lower than
those elicited by stimuli and than those generated by CF PMNs,
indicating that the higher baseline ROS production observed in
CF PMNs could be considered as truly different from that of
control subjects. Nevertheless, it has been reported controver-
sially that ROS production by CF blood PMN can be higher
than [27] or identical to [28] that of healthy controls. In other
studies, ROS generation varied according to the infecting
pathogen [16] or to the method employed to detect respiratory
burst activity [15]. Our results showing a higher ROS
production at the baseline in CF blood PMNs as compared
with controls PMNs, suggest that CF PMNs are primed in the
circulation. Although we have not measured the levels of serum
cytokines, since the patients considered in this study were all in
acute exacerbation, it is likely that this primed state reflects an
increase in circulating pro-inflammatory mediators, also con-
sistent with the higher IL-8 levels produced by CF PMNs at the
baseline as compared with healthy PMNs. It is noteworthy that
our results concerning IL-8 production are in agreement withthose obtained by Corvol and colleagues [13], who similarly
showed that PMNs from CF patients in acute state constitu-
tively secrete higher amounts of IL-8 than those from control
subjects. However, higher baseline levels of ROS and IL-8 could
be explained also by a genetic component. Differential responses
of CF and non-CF patients concerning L-selectin shedding [18],
myeloperoxidase-dependent oxygenation activities [15], elastase
release [11], and IL-8 production [13] suggest a relationship
between altered PMN functions and CFTR mutations. Never-
theless, these differences in IL-8 production are unlikely due to the
apoptosis since PMN apoptosis in basal conditions was found at
similar level in controls and patients (Fig. 3).
In our study, while ROS production is insensitive to antibiotic
treatment, as also demonstrated by a previous study [29], PMNs
respond to antibiotics with a significant increase in IL-8 secretion.
The levels of other pro-inflammatory cytokines showed a trend to
decrease for IL-1β and a significant lower level for IL-6 after
therapy, ruling out that the effect on IL-8 was unspecific.
In previous studies, ciprofloxacin did not exhibit stimulatory
effect on ROS in blood PMNs, while normal ROS production
was increased by pyoverdin [30]. Antibiotics can modulate the
in vitro synthesis of pro-inflammatory cytokines by LPS-primed
PMNs; in particular, the β-lactam co-amoxiclav promoted an
increase of IL-8 especially when Klebsiella penumoniae was
present, and tobramycin induced the production of IL-6 and
TNF-α [31], indicating that antibiotics can potentiate PMN
functions. However, another drug used in the present study,
azithromycin, did not affect oxidative metabolism and IL-8
production of PMNs obtained from healthy subjects [32]. The
low numbers of patients investigated in this study does not allow
any conclusive consideration on the effect of antibiotic regimen
on ROS and cytokine production by CF PMNs, and this could
be only ruled out by analysing consistent groups of patients
receiving different antibiotic treatments.
It was previously reported that serum concentration of IL-8
was higher in non-infected than in chronically infected CF
patients [33]. IL-8 is a multi-faceted chemokine and its effect on
the number of PMNs released from bone marrow is governed by
multiple mechanisms. Indeed, IL-8 increases the mobilisation of
PMNs [34], but inhibits the neutropoiesis in the marrow [35,36].
The downstream effect on the lung extravasation of PMNs is
uncertain at the moment, however we have found in 7 out of the
14 patients included in this study a reduction in sputum PMN
numbers following therapy (7.27±1.96 vs. 5.15±1.66×106)
Therefore, higher levels of blood IL-8 in CF patients after
antibiotic treatment may indicate a therapeutic effect useful to
dampen the number of PMNs infiltrating the CF airways.
Fig. 3. Survival and apoptosis in circulating PMNs. PMNs obtained from control
subjects (ctrl), CF patients before (pre), and after therapy (post), were assayed at
isolation (A) and after incubation in the absence (B) or the presence of PMA (C).
Results are shown as percentage of cells according to the differential labelling with
Annexin V (V) and 7-amino-actinomycin (ADD). Data are presented by box and
whiskers (25th and 75th percentile) and median (solid line). Data were analysed by
Wilcoxon signed rank test for comparison between pre- and post-therapy and by
Wilcoxon rank unpaired test for comparison between controls and patients (pre- and
post-therapy).
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higher apoptotic rate than non-CF subjects. On the other hand,
two previous studies [19,20] demonstrated a delayed apoptosis in
blood PMNs obtained from stable CF patients as compared with
non-CF controls. Since our study considered only acute CF
patients, these results may indicate that CF PMNs are primed to
enhanced apoptosis during an acute exacerbation. This enhanced
apoptosis may contribute to the CF lung disease, since PMNs aretargeted by P. aeruginosa, disabled for their surface receptors
such as CXCR1, undergoing apoptosis and secondary necrosis
[8]. Indeed, P. aeruginosa impairs PMN bactericidal function in
part by producing toxins and secondary metabolites, including
pyocyanin, that accelerate PMN death and inhibit the removal of
apoptotic PMN corpses by macrophages [9,37]. This accelerated
PMN death and failed clearance can been seen in individuals with
CF who are infected with P. aeruginosa [3] and has two
outcomes: a decreased pool of viable PMNs able to engage and
kill P. aeruginosa and the release of various toxic antimicrobial
molecules, including proteases, from necrotic neutrophils.
To the best of our knowledge, no data are available on the
response of circulating PMN apoptosis to the antibiotic treatment
in CF patients. Our results show that the therapy for an acute
exacerbation does not influence the apoptotic response of
circulating PMN apoptosis, which remains at high levels,
suggesting that none of the administered drug in this study can
modulate this PMN response. Interestingly, it has been reported
that the enhancing effect of azithromycin on the PMN apoptosis is
inhibited when S. penumoniae is present [32]. LPS of Gram-
negative bacteria has been shown to inhibit TNF-α-induced
apoptosis [38]. K. pneumoniae was able to further increase the
inhibition of PMN apoptosis induced by various antibiotics [39].
Altogether these data suggest that serum cytokines and bacterial
products may reverse or inhibit the pro-apoptotic effect of
antibiotics, causing further tissue injury by the pathogens.
5. Conclusions
This study shows that circulating PMNs are primed for ROS
and IL-8 production prior to extravasate into the lung of CF
patients during an episode of acute exacerbation, confirming
previous results. Whether this is due to the shedding of pro-
inflammatory mediators from the chronically infected lung or to a
genetically determined activation status is to be determined. A
novel finding is that also the early apoptotic response is higher and
this may contribute to the clinical worsening of these patients, since
apoptosis and secondary necrosis are part of the inflammatory
vicious cycle of the CF lung. We are investigating which pro-
apoptotic pathway is causing this alteration. On the other hand,
apoptotic response was not modified by antibiotic therapy,
paralleled by the lack of effect on ROS production in treated
patients, and this may be due to the complex interplay between
antibiotic mode of action and primed state of PMNs due to
bacterial products. Finally, IL-8 production by blood PMNs may
be envisioned as a novel biomarker, “specific” and sensitive to
therapy in a non-invasiveway, although higher numbers of patients
are needed to confirm this conclusion.
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